NEWEarnings

UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer

Published on 7/16/2026

#URGN#Earnings#Oppenheimer
UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer

AI Summary

Summarized by AI from the source below

Oppenheimer has increased the price target of UroGen Pharma (URGN) to $50, driven by positive sales outlook. This adjustment reflects expectations for future revenue growth and potential market performance. The revised target indicates increased confidence in UroGen's business trajectory. This news is significant for investors as it may influence stock performance and investor sentiment toward UroGen Pharma.

Share:
Source: Read original article (opens in new tab)

Get the free market brief

Top stories and analysis, summarized. No spam, unsubscribe anytime.

Related News

JPMorgan Chase Earnings Report Shows Growth Potential Ahead
Earnings

JPMorgan Chase Earnings Report Shows Growth Potential Ahead

Jul 16

Morgan Stanley (MS) Q2 2026 Profit Jumps 60% to $5.6 Billion
Earnings

Morgan Stanley (MS) Q2 2026 Profit Jumps 60% to $5.6 Billion

Jul 16

Uber (UBER) Acquires Delivery Hero for $14.8 Billion Deal
M&A

Uber (UBER) Acquires Delivery Hero for $14.8 Billion Deal

Jul 16

Newgen Q1 FY'27 Profit Surges 26%, Shares Slip Over Mix Concerns
Earnings

Newgen Q1 FY'27 Profit Surges 26%, Shares Slip Over Mix Concerns

Jul 16